Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Markéta Kovalová, Joseph Peter Baraka, Václav Mik, Radek Jorda, Lei Luo, Hao Shao & Vladimír Kryštof. (2023) A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022). Expert Opinion on Therapeutic Patents 33:2, pages 67-87.
Read now
Read now
Hanzhi Liang, Jintong Du, Reham M. Elhassan, Xuben Hou & Hao Fang. (2021) Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. Expert Opinion on Investigational Drugs 30:1, pages 61-76.
Read now
Read now
Dan Lin, Xiaoyang Lin, Tianlin He & Guoqun Xie. (2020) Gambogic Acid Inhibits the Progression of Gastric Cancer via circRNA_ASAP2/miR-33a-5p/CDK7 Axis. Cancer Management and Research 12, pages 9221-9233.
Read now
Read now
Articles from other publishers (24)
Markéta Kovalová, Libor Havlíček, Stefan Djukic, Jana Škerlová, Miroslav Peřina, Tomáš Pospíšil, Eva Řezníčková, Pavlína Řezáčová, Radek Jorda & Vladimír Kryštof. (2023) Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7. Biomedicine & Pharmacotherapy 161, pages 114492.
Crossref
Crossref
Aadil Javed, Mahdieh Yarmohammadi, Kemal Sami Korkmaz & Teresa Rubio-Tomás. (2023) The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer. International Journal of Molecular Sciences 24:3, pages 2848.
Crossref
Crossref
Zhi-Mei Li, Guan Liu, Ya Gao & Ming-Gao Zhao. (2022) Targeting CDK7 in oncology: The avenue forward. Pharmacology & Therapeutics 240, pages 108229.
Crossref
Crossref
Xintong Li, Lin Tang, Qin Chen, Xumin Cheng, Yiqiu Liu, Cenzhu Wang, Chengjun Zhu, Kun Xu, Fangyan Gao, Jinyi Huang, Runtian Wang & Xiaoxiang Guan. (2022) Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer. Chinese Medical Journal 135:20, pages 2436-2445.
Crossref
Crossref
Xiaoyang Li, Dylan C. Dean, Jin Yuan, Thomas H. Temple, Jonathan C. Trent, Andrew E. Rosenberg, Shengji Yu, Francis J. Hornicek & Zhenfeng Duan. (2022) Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma. Biomedicine & Pharmacotherapy 149, pages 112888.
Crossref
Crossref
Jin Yuan, Xiaoyang Li & Shengji Yu. (2022) CDK7-dependent transcriptional addiction in bone and soft tissue sarcomas: Present and Future. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:2, pages 188680.
Crossref
Crossref
Yueyuan Wang, Jingyu Peng, Xuguang Mi & Ming Yang. (2021) p53–GSDME Elevation: A Path for CDK7 Inhibition to Suppress Breast Cancer Cell Survival. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Paweł Łukasik, Michał Załuski & Izabela Gutowska. (2021) Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review. International Journal of Molecular Sciences 22:6, pages 2935.
Crossref
Crossref
Vaishnavi Sundar, Sanjana Vimal, M.s. Sai Mithlesh, Anupam Dutta, Ramasamy Tamizhselvi & Venkatraman Manickam. (2021) Transcriptional cyclin-dependent kinases as the mediators of inflammation-a review. Gene 769, pages 145200.
Crossref
Crossref
Shin Young Park, Ki Yun Kim, Do Youn Jun, Su-Kyeong Hwang & Young Ho Kim. (2020) G1 Cell Cycle Arrest and Extrinsic Apoptotic Mechanisms Underlying the Anti-Leukemic Activity of CDK7 Inhibitor BS-181. Cancers 12:12, pages 3845.
Crossref
Crossref
Wonjun Ji, Yun Jung Choi, Myoung-Hee Kang, Ki Jung Sung, Dong Ha Kim, Sangyong Jung, Chang-Min Choi, Jae Cheol Lee & Jin Kyung Rho. (2020) Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines. Cells 9:12, pages 2596.
Crossref
Crossref
Jianru Zhang, Xiaoyun Zhang, Huidan Huang & Yimei Ding. (2020) A review on kinases phosphorylating the carboxyl-terminal domain of RNA polymerase II—Biological functions and inhibitors. Bioorganic Chemistry 104, pages 104318.
Crossref
Crossref
Georgina P. Sava, Hailing Fan, R. Charles Coombes, Lakjaya Buluwela & Simak Ali. (2020) CDK7 inhibitors as anticancer drugs. Cancer and Metastasis Reviews 39:3, pages 805-823.
Crossref
Crossref
Sarah Diab, Mingfeng Yu & Shudong Wang. (2020) CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?. Journal of Medicinal Chemistry 63:14, pages 7458-7474.
Crossref
Crossref
Minmin Wang, Tianyu Wang, Xiangyu Zhang, Xiaoxing Wu & Sheng Jiang. (2020) Cyclin-dependent kinase 7 inhibitors in cancer therapy. Future Medicinal Chemistry 12:9, pages 813-833.
Crossref
Crossref
Jordan L Kohlmeyer, David J Gordon, Munir R Tanas, Varun Monga, Rebecca D Dodd & Dawn E Quelle. (2020) CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. International Journal of Molecular Sciences 21:8, pages 3018.
Crossref
Crossref
Yuou Teng, Kui Lu, Qian Zhang, Lianbo Zhao, Yuna Huang, Angela Maria Ingarra, Hervé Galons, Tingshen Li, Shanshan Cui, Peng Yu & Nassima Oumata. (2019) Recent advances in the development of cyclin-dependent kinase 7 inhibitors. European Journal of Medicinal Chemistry 183, pages 111641.
Crossref
Crossref
Emma K. Grant, David J. Fallon, H. Christian Eberl, Ken G. M. Fantom, Francesca Zappacosta, Cassie Messenger, Nicholas C. O. Tomkinson & Jacob T. Bush. (2019) A Photoaffinity Displacement Assay and Probes to Study the Cyclin‐Dependent Kinase Family. Angewandte Chemie International Edition 58:48, pages 17322-17327.
Crossref
Crossref
Emma K. Grant, David J. Fallon, H. Christian Eberl, Ken G. M. Fantom, Francesca Zappacosta, Cassie Messenger, Nicholas C. O. Tomkinson & Jacob T. Bush. (2019) A Photoaffinity Displacement Assay and Probes to Study the Cyclin‐Dependent Kinase Family. Angewandte Chemie 131:48, pages 17483-17488.
Crossref
Crossref
Calla M. Olson, Yanke Liang, Alan Leggett, Woojun D. Park, Lianbo Li, Caitlin E. Mills, Selma Z. Elsarrag, Scott B. Ficarro, Tinghu Zhang, Robert Düster, Matthias Geyer, Taebo Sim, Jarrod A. Marto, Peter K. Sorger, Ken D. Westover, Charles Y. Lin, Nicholas Kwiatkowski & Nathanael S. Gray. (2019) Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chemical Biology 26:6, pages 792-803.e10.
Crossref
Crossref
Liqiang Zhong, Sihao Yang, Yuming Jia & Kaijian Lei. (2018) Inhibition of cyclin‐dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis. Journal of Cellular Biochemistry 119:12, pages 9742-9751.
Crossref
Crossref
Juan Duan, Yan He, Xiaolin Fu, Yujie Deng, Min Zheng & Dongdong Lu. (2018) CDK7 activated beta-catenin/TCF signaling in hepatocellular carcinoma. Experimental Cell Research 370:2, pages 461-467.
Crossref
Crossref
Honghai Hong, Yingmin Zeng, Wenxuan Jian, Lei Li, Liying Lin, Yousheng Mo, Meiling Liu, Shuhuan Fang & Yong Xia. (2017)
CDK
7 inhibition suppresses rheumatoid arthritis inflammation
via
blockage of
NF
‐κB activation and
IL
‐1β/
IL
‐6 secretion
. Journal of Cellular and Molecular Medicine 22:2, pages 1292-1301.
Crossref
Crossref
Pascale Hazel, Sebastian H. B. Kroll, Alexander Bondke, Marion Barbazanges, Hetal Patel, Matthew J. Fuchter, R Charles Coombes, Simak Ali, Anthony G. M. Barrett & Paul S. Freemont. (2017) Inhibitor Selectivity for Cyclin‐Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study. ChemMedChem 12:5, pages 372-380.
Crossref
Crossref